Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly

Biosensores para el riego y la evaluacion del estado hidrico de arboles frutales

International audienc

Interaction of PLGA Nanoparticles with human plasma proteins

Trabajo presentado en Latest Advances on Nanomaterials for Biomedical Application (NANOBIOAPP 2015), celebrado en Barcelona entre el 21 y el 23 de septiembre de 2015Peer reviewe

Interaction of PLGA Nanoparticles with human plasma proteins

Trabajo presentado en el VII Workshop CBN 2015, 7ª Jornada del Departamento de Nanotecnología Química y Biomolecular del IQAC, celebrado en Barcelona el 15 de octubre de 2015

Behavioral asymmetries and recovery in rats with different degrees of unilateral striatal dopamine depletion

A detailed behavioral analysis during the first postoperative week was performed in rats which had sustained various degrees of unilateral neostriatal dopamine (DA) lesions by administration of the neurotoxin 6-hydroxydopamine into the substantia nigra. These animals were assigned to different groups according to their residual DA levels in the damaged neostriatum (as percentage of the intact side). On the first day after toxin injection into the substantia nigra, turning asymmetries (tight turns) toward the side of the lesion were observed in animals with a mean residual DA level of 32% or less. Out of these, the strongest asymmetries were observed in animals with a mean residual DA of 3%. After one week, the asymmetry in tight turns had totally recovered except in those groups with mean residual DA levels of 17% or less. Partial recovery was found in animals with mean residual DA of 9 and 17%, whereas no indication for recovery was found in animals with the most severe lesions (mean residual DA 3%). Measurement of thigmotactic scanning also revealed an asymmetry for the side of the lesion on the first post-operative day. This asymmetry was observed over a wider range of DA lesion than that observed in turning, namely up to a mean residual DA level of 78%. Furthermore, recovery to symmetry was observed in all lesion-groups except in those with more severe lesions (mean residual DA 17% or less). In contrast to turning, the strongest asymmetries were not displayed by the animals with the most severe lesions. Furthermore, locomotor activity was affected by the lesion, since on the first postoperative day locomotion was reduced in animals with mean residual DA of 39% or less. On day 7, this lesion-dependent deficit had recovered to control levels. Finally, the analysis of net turns allowed the prediction of lesion size in animals with residual DA levels of less than 15%. These results are discussed with respect to mechanisms of recovery, the role of lesion size, and the value of different behavioral measures to predict the degree of DAergic lesion.Deutsche Forschungsgemeinschaft/[Hu 306/13-1]/DFG/AlemaniaUCR::Vicerrectoría de Docencia::Salud::Facultad de Medicina::Escuela de MedicinaUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Neurociencias (CIN

Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases

Polymeric nanoparticles could be promising drug delivery systems to treat neurodegenerative diseases. Among the various methods of nanoparticle preparation, nano-emulsion templating was used in the present study to prepare galantamine-loaded nano-emulsions by a low-energy emulsification method followed by solvent evaporation to obtain galantamine-loaded polymeric nanoparticles. This approach was found to be suitable because biocompatible, biodegradable and safe nanoparticles with appropriate features (hydrodynamic radii around 20 nm, negative surface charge and stability higher than 3 months) for their intravenous administration were obtained. Encapsulation efficiencies higher than 90 wt% were obtained with a sustained drug release profile as compared to that from aqueous and micellar solutions. The enzymatic activity of the drug was maintained at 80% after its encapsulation into nanoparticles that were non-cytotoxic at the required therapeutic concentration. Therefore, novel galantamine-loaded polymeric nanoparticles have been designed for the first time using the nano-emulsification approach and showed the appropriate features to become advanced drug delivery systems to treat neurodegenerative diseases.Financial support from MINECO (grant CTQ2011-29336-CO3-O1), Generalitat de Catalunya (grant 2009-SGR-961) and CIBER-BBN (financed by the Instituto de Salud Carlos III) is acknowledged. Cristina Fornaguera is grateful to AGAUR for their Pre-doctoral Fellowship (grant FI-DGR 2012).Peer reviewe